OBJECTIVE: To probe into the clinical efficacy of Guizhi Fuling capsules combined with Drospirenone and ethinylestradiol tablets in the treatment of recurrent ovarian endometriosis cysts. METHODS: Totally 62 patients with recurrent ovarian endometriosis cysts admitted into Beijing Tongren Hospital from Jan. 2018 to Jan. 2021 were retrospectively extracted to be divided into the control group and the observation group according to different treatment regimens

with 31 cases in each group. The control group received Drospirenone and ethinylestradiol tablets at bedtime of every night on the first day of menstruation for 21 d

and the next cycle was started on the 7 th d after withdrawal.The observation group was given orally Guizhi Fuling capsules after three meals on the basis of the control group. Both groups were continuously treated for 6 menstrual cycles. Differences in clinical efficacy and medication safety between two groups were compared. The visual analogue scale（ VAS）

pelvic mass diameter and CA125 level were observed before and after treatment in two groups. RESULTS: The total effective rates in the observation group and the control group were respectively 95. 16%（ 59/62） and 80. 65%（ 50/62）. The comparison of clinical efficacy showed that the observation group were significantly better than the control group

and the difference was statistically significant（ P <0. 05）. Compared with before treatment

after treatment

VAS score

pelvic mass diameter and CA125 level were decreased significantly in two groups

the above indicators in the observation group were significantly better than those in the control group

with statistically significant difference（ P < 0. 05）. The incidences of adverse drug reactions in the control and the observation groups were respectively 9. 68%（ 6/62） and 8. 06%（ 5/62）

with no statistically significant difference（ P > 0. 05）. CONCLUSIONS: Guizhi Fuling capsules combined with Drospirenone and ethinylestradiol tablets in the treatment of recurrent ovarian endometriosis cysts can significantly improve patients’ dysmenorrhea and chronic pelvic pain

reduce the pelvic mass diameter and improve patients’ quality of life

which has certain clinical application value.